Search

everythinglearnresearchcommunity

for

Search:↓

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

The user wants to try using 0.025% topical finasteride every day by diluting their 0.1% topical finasteride with alfatradiol, and is asking if it's possible to mix them or if there are other options. They heard that alfatradiol might not be suitable for this purpose.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.

The conversation is about adjusting the dosage of topical Finasteride to avoid side effects like chest pain and breast swelling. The user is considering reducing the concentration to 0.1% or trying microdosing with 0.01-0.025% for lower systemic effects.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

A user's experience with using 5AR inhibitors (Finasteride and Dutasteride) in combination with Minoxidil foam and microneedling, which resulted in substantial improvements to their crown density and hairline, despite high systemic levels of testosterone and dihydrotestosterone.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.

A 25-year-old shared their 3-month progress using a combination of 1mg finasteride and 5% minoxidil for hair loss. The images show noticeable improvement in hair density.

A man in his late twenties switched from finasteride to dutasteride for hair loss and is sharing his 3-month progress, noting increased shedding but no side effects. Some responders think the treatment is working.

A user shared progress pictures showing significant hair improvement after using a topical 0.3% finasteride/6% minoxidil solution from January to June 2024. They experienced initial shedding but saw progressive improvement with daily evening application.

The user experienced significant hair maintenance using 0.25mg daily finasteride and minoxidil foam, with minimal side effects. They recommend oral finasteride for better results, especially for the crown area.

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The conversation is about the effectiveness of 0.25% topical finasteride compared to other concentrations and forms. Users discuss its potential for better scalp DHT reduction and fewer side effects, with some preferring topical over oral treatments.

The user is considering stopping finasteride after 1.8 years due to concerns about side effects and is exploring alternatives like minoxidil and topical finasteride. They are also considering microneedling and are advised to wait for new treatments like breezula/clascoterone.

The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

User reports 3-month progress using daily 1mg finasteride, 0.5ml minoxidil (2x daily), 0.5ml dutasteride, and derma rolling 0.5mm 1-2 times per week. They see increased density on crown and top of head, slight progress in corners and temples, and recently added cosmerna.

The user is asking if using a 10% fluridil formulation would be effective for blocking scalp androgens in addition to their current treatment of oral dutasteride.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.